Typhoid vaccine study seeks immune clues

NCT ID NCT03971669

Recruiting now Knowledge-focused Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study gives healthy adults the licensed oral typhoid vaccine (Vivotif) and collects blood, saliva, and stool samples over up to eight years. Researchers want to learn how the vaccine triggers protective immune responses, which could help design better vaccines for typhoid and other gut infections. The study involves 150 volunteers and is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vivotif (oral typhoid vaccine)
What this could lead to: If successful, this could help researchers develop better vaccines for typhoid and other gut infections.
What could go wrong: This is an observational study focused on immune responses, not a treatment trial. Results may not directly lead to new vaccines or therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RISK REDUCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Risk Reduction Behavior typhoid fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RISK REDUCTION

Contacts and locations

Locations

University of Maryland, Baltimore, Center for Vaccine Development and Global Health
RECRUITING

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.